Read More Biotech General News Lexaria Receives Ethics Review Board Approval To Begin New GLP-1 Study, Investigating GLP-1 Drugs And DehydraTECH By Benzinga Newsdesk April 16, 9:17 AM Human Pilot Study #2 (GLP-1-H24-2) ApprovedKELOWNA, BC / ACCESSWIRE / April 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, LEXX
Read More Bonds Equities Global Markets News Politics Trump Victory ‘More Bearish’ For Debt Market Than A Biden Win, Warns ‘Bond King’ Bill Gross By Benzinga Neuro May 27, 12:59 AM Bill Gross, the renowned fixed-income investor, has expressed concerns about the potential impact of a Donald Trump re-election on the bond markets. DJT
Read More Analyst Ratings News Price Target Wells Fargo Maintains Overweight on BJ’s Wholesale Club, Raises Price Target to $80 By Benzinga Newsdesk February 6, 9:28 AM Wells Fargo analyst George Kelly maintains BJ's Wholesale Club (NYSE:BJ) with a Overweight and raises the price target from $78 to $80. BJ
Read More Analyst Color Analyst Ratings Equities General Markets News Price Target Reiteration Trading Ideas Levi Strauss’ Resilience In The Face Of Sluggish Demand – An Analyst’s Perspective On The Outperform Rating By Shivani Kumaresan July 7, 2:22 PM Telsey Advisory Group analyst Dana Telsey reiterated an Outperform rating on the shares of Levi Strauss & Co (NYSE: LEVI) and LEVI